4.3 Article

A radiocalibration method with pseudo internal standard to estimate circulating metabolite concentrations

期刊

BIOANALYSIS
卷 2, 期 7, 页码 1195-1210

出版社

FUTURE SCI LTD
DOI: 10.4155/BIO.10.81

关键词

-

向作者/读者索取更多资源

Background: It has become important for metabolism scientists to identify and quantify prominent circulating human metabolites in order to develop a metabolite safety-qualification package that meets regulatory standards. Often these metabolites cannot be analyzed using traditional bioanalytical methods because a standard is not available. Results: A radiocalibration method is described that can estimate circulating metabolite concentrations in nonradioactive human and animal plasma. The key to this method is application of a pseudo internal standard (PIS) that is present in both radioactive reference and nonradioactive (i.e., unknown) samples. Metabolite exposure in the unknown samples is estimated from measured PIS exposure using a relative molar ratio established between the metabolite and PIS (usually parent drug). Conclusion: Two case studies demonstrate that the method can be used to establish human metabolite safety coverage in animal plasma and method validation is demonstrated by comparing estimated metabolite concentrations in human plasma with concentrations obtained directly using a metabolite calibration curve.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Chemistry, Medicinal

Discovery of the First α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonist Dependent upon Transmembrane AMPA Receptor Regulatory Protein (TARP) γ-8

Kevin M. Gardinier, Douglas L. Gernert, Warren J. Porter, Jon K. Reel, Paul L. Ornstein, Patrick Spinazze, F. Craig Stevens, Patric Hahn, Sean P. Hollinshead, Daniel Mayhugh, Jeff Schkeryantz, Albert Khilevich, Oscar De Frutos, Scott D. Gleason, Akihiko S. Kato, Debra Luffer-Atlas, Prashant V. Desai, Steven Swanson, Kevin D. Burris, Chunjin Ding, Beverly A. Heinz, Anne B. Need, Vanessa N. Barth, Gregory A. Stephenson, Benjamin A. Diseroad, Tim A. Woods, Hong Yu, David Bredt, Jeffrey M. Witkin

JOURNAL OF MEDICINAL CHEMISTRY (2016)

Editorial Material Biochemistry & Molecular Biology

A decade of drug metabolite safety testing: industry and regulatory shared learning

Debra Luffer-Atlas, Aisar Atrakchi

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)

Article Pharmacology & Pharmacy

Serum Lipid and Protein Changes in Healthy Dyslipidemic Subjects Given a Selective Inhibitor of p70 S6 Kinase-1

Jennifer K. Leohr, Debra Luffer-Atlas, M. Jane Luo, David J. DeBrota, Colin Green, Thomas E. Mabry, Jeffrey G. Suico

JOURNAL OF CLINICAL PHARMACOLOGY (2018)

Article Pharmacology & Pharmacy

Identification of 4-Aminopyrazolopyrimidine Metabolite That May Contribute to the Hypolipidemic Effects of LY2584702 in Long Evans Diet-Induced Obese Rats

Thomas B. Estridge, Asim B. Dey, Charles Reidy, Xiaohong Yu, Yuke Zhang, Maryalice Hartley, Paul L. Milligan, Najia Jin, Mark C. Kowala, Jennifer K. Leohr, Adrian J. Fretland, Thomas E. Mabry, Debra Luffer-Atlas, M. Jane Luo

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)

Article Chemistry, Medicinal

Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin E Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury

Bryan H. Norman, Matthew J. Fisher, Matthew A. Schiffler, Steven L. Kuklish, Norman E. Hughes, Boris A. Czeskis, Kenneth C. Cassidy, Trent L. Abraham, Jeffrey J. Alberts, Debra Luffer-Atlas

JOURNAL OF MEDICINAL CHEMISTRY (2018)

Article Pharmacology & Pharmacy

The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor

William Kielbasa, Eshetu Tesfaye, Debra Luffer-Atlas, Malcolm I. Mitchell, Michael A. Turik

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)

Article Radiology, Nuclear Medicine & Medical Imaging

Evaluation in vitro and in animals of a new 11C-labeled PET radioligand for metabotropic glutamate receptors 1 in brain

Paolo Zanotti-Fregonara, Vanessa N. Barth, Jeih-San Liow, Sami S. Zoghbi, David T. Clark, Emily Rhoads, Edward Siuda, Beverly A. Heinz, Eric Nisenbaum, Bruce Dressman, Elizabeth Joshi, Debra Luffer-Atlas, Matthew J. Fisher, John J. Masters, Nancy Goebl, Steven L. Kuklish, Cheryl Morse, Johannes Tauscher, Victor W. Pike, Robert B. Innis

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)

Review Biochemistry & Molecular Biology

The early estimation of circulating drug metabolites in humans

Debra Luffer-Atlas

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)

Article Biochemical Research Methods

Overview of metabolite safety testing from an industry perspective

Shelby Anderson, Mary Pat Knadler, Debra Luffer-Atlas

BIOANALYSIS (2010)

Article Developmental Biology

PDGFRα monoclonal antibody: Assessment of embryo-fetal toxicity and time-dependent placental transfer of a murine surrogate antibody of olaratumab in mice

Debra Luffer-Atlas, Vijayapal R. Reddy, Kim G. Hilbish, Curtis E. Grace, William J. Breslin

BIRTH DEFECTS RESEARCH (2018)

Review Chemistry, Medicinal

A MIST conception: what has been learned from twenty years of human metabolite safety assessment?

Debra Luffer-Atlas, R. Scott Obach, Dennis A. Smith

Summary: In this review, the origins and developments of the joint initiative by the pharmaceutical industry and regulatory authorities to establish a framework for the identification, quantification, and testing of drug metabolites (MIST) are traced. The current approaches and techniques for metabolite assessment in the industry are described, along with case studies demonstrating the limited usefulness of additional nonclinical safety assessment for disproportionate human metabolites. The impact of MIST guidelines on drug safety and industry productivity for new molecular entities is discussed.

MEDICINAL CHEMISTRY RESEARCH (2023)

Article Pharmacology & Pharmacy

Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-Glycoprotein and Breast Cancer Resistance Protein Substrates

Debra Luffer-Atlas, Darren Wilbraham, Maria M. Posada, John Landry, Max Tsai, Eric M. Pearlman

Summary: The study aimed to evaluate the safety and tolerability of the interaction between Lasmiditan and the drugs rosuvastatin and dabigatran. The results suggest that Lasmiditan has a weak effect on P-gp substrates and no clinically relevant effect on BCRP substrates.

JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Oncology

Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α

Caitlin D. Lowery, Wayne Blosser, Michele Dowless, Shelby Knoche, Jennifer Stephens, Huiling Li, David Surguladze, Nick Loizos, Debra Luffer-Atlas, Gerard J. Oakley, Qianxu Guo, Seema Iyer, Brian P. Rubin, Louis Stancato

CLINICAL CANCER RESEARCH (2018)

Article Pharmacology & Pharmacy

Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer

Gary Mo, John R. Baldwin, Debra Luffer-Atlas, Robert L. Ilaria, Ilaria Conti, Michael Heathman, Damien M. Cronier

CLINICAL PHARMACOKINETICS (2018)

暂无数据